Poster Session B
Sunday, Sept. 23, 2018
5:45-8 p.m.

B001. Association of Cytokinome and tumor infiltrating lymphocytes with MMR and HR deficiency in pancreatic cancer. Joan Miguel Romero, Department of Laboratory Medicine and Pathobiology, University of Toronto; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

B002. B cell receptor activation drives immunosuppression by IL-35+ regulatory B cells in pancreatic cancer. Dan Michaud, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.

B003. Development of a personalized platform to predict immune reactivity and efficacy of immune checkpoint blockade in pancreas cancer. Lawrence Delrosario, University of Michigan, Ann Arbor, MI, USA.

B004. Dissecting the endogenous T cell response in an autochthonous mouse model of PDAC. William Freed-Pastor, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA.

B005. IL-35+ B cells establish immunosuppressive network in pancreatic ductal adenocarcinoma. Yuliya Pylayeva-Gupta, UNC Chapel Hill, Chapel Hill, NC, USA.

B006. Immune cell populations regulated by the MST1R kinase in pancreatic cancer. Alex Cazes, Moores Cancer Center, University of California, San Diego, CA, USA.

B007. Leveraging neo-adjuvant chemotherapy to modulate immune targets in pancreatic ductal adenocarcinoma. Matthew Farren, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

B008. PD-L1 diminishes the tumor suppressive effects of TGF-β in pancreatic ductal adenocarcinoma. Marcus Alvarez, University of Tennessee Health Science Center, Memphis, TN, USA.

B009. Tumor-cell-intrinsic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer. Jinyang Li, University of Pennsylvania, Philadelphia, PA, USA.


B011. Augmenting T cell immunity to pancreatic cancer using IAP (inhibitor of apoptosis protein) antagonists. Stephanie Dougan, Dana-Farber Cancer Institute, Boston, MA, USA.

B012. Chemotherapy enhances immune recognition of pancreatic cancer associated antigens suitable for DNA vaccination. Francesco Novelli, University of Turin, Department of Molecular Biotechnology and Health Sciences, Turin, Italy.
Poster Session B  
Sunday, Sept. 23, 2018  
5:45-8 p.m.

B013. CXCR1/2 inhibition with checkpoint blockade enhances chemotherapy responses in pancreatic ductal adenocarcinoma. Booyeon Han, University of Rochester Medical Center, Rochester, NY, USA.

B014. IMMUNOREGULATION BY HUMAN WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELLS AND ITS SECRETOMES: EFFECT ON PANCREATIC CANCER CELLS. Sangeeta Choudhury, Sir Ganga Ram Hospital, New Delhi, Delhi, India.

B015. Inhibition of C-X-C motif chemokine receptor 4 (CXCR4) in combination with chemotherapy and immunotherapy prolongs survival in a genetically engineered model of pancreatic cancer. Gulam Manji, Columbia University Medical Center, New York, NY, USA.


B017. NK cells limit pancreatic tumor growth through immune mobilization, selection and differentiation of stem-like/poorly differentiated tumors in humanized-BLT mice. Kawaljit Kaur, UCLA, LA, CA, USA.

B018. Overcoming immune privilege in pancreatic cancer: A Phase I trial of the CXCR4 inhibitor, plerixafor (AMD3100), administered by continuous i.v. infusion. Duncan Jodrell, University of Cambridge, Cambridge, UK.

B019. Stereotactic body radiation and Interleukin 12 combination therapy for the treatment of advanced pancreatic cancer. Bradley Mills, University of Rochester, Rochester, NY, USA.


B021. The TLR7/8 agonist R848 induces antitumor responses, attenuates cachexia, and improves survival in a murine model of pancreatic ductal adenocarcinoma. Katherine Michaelis, Oregon Health and Science University, Portland, OR, USA.

B022. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer. Daniela Basseres, University of São Paulo, São Paulo, SP, Brazil.

B023. Blocking SIAH proteolysis, an important K-RAS signaling vulnerability, to control and eradicate oncogenic K-RAS-driven metastatic pancreatic cancer. Amy Tang, Eastern Virginia Medical School, Norfolk, VA, USA.

B024. Defining and targeting resistance to pharmacologic KRAS inhibition in pancreatic cancer using quantitative proteomics. Joseph Mancias, Dana-Farber Cancer Institute, Boston, MA, USA.
**B025. Drp1 promotes KRas-driven metabolic changes and pancreatic tumor growth.** Sarbajeet Nagdas, University of Virginia Health System, Charlottesville, VA, USA.

**B026. Identifying protein interactors of oncogenic K-ras in pancreatic cancer cells.** Derek Cheng, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

**B027. Mouse modeling sporadic LOH at Kras locus in pancreatic cancer by mosaic analysis with double markers.** WANGLONG QIU, Columbia University Medical Center, NEW YORK, NY, USA.

**B028. Protective autophagy elicited by RAF-MEK-ERK inhibition suggests a treatment strategy for RAS-driven cancers.** Conan Kinsey, Huntsman Cancer Institute, Salt Lake City, UT, USA.

**B029. Targeting KRAS translation with a specific eIF4A inhibitor as therapeutics in pancreatic cancer.** Kamini SIngh, Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

**B030. Activation-induced cytidine deaminase facilitates acinar-to-ductal metaplasia in response to inflammatory injury through an Oct4-dependent mechanism.** Robert Cowan, MD Anderson, Houston, TX, USA.

**B031. Activity of Yes-associated protein is promoted by activation of free fatty acid receptors 1 and 4 in pancreatic cancer cells.** Hui-Hua Chang, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

**B032. Calcium signaling induces a partial EMT in pancreatic ductal adenocarcinoma.** Robert Norgard, University of Pennsylvania, Philadelphia, PA, USA.

**B033. Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness.** Bernhard Renz, Department of General, Visceral, and Transplantation Surgery, Hospital of the LMU Munich, Munich, Germany.

**B034. CRISPR Screen Identifies DUSP11 as a regulator of gemcitabine response in pancreatic carcinoma cell lines.** Vanessa Silveira, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.

**B035. CXCL12 activates CREB and accelerates fibrosis in response to alcohol-induced pancreatic carcinogenesis.** Supriya Srinivasan, University of Miami Miller School of Medicine, Miami, FL, USA.

**B036. GLI2 activation drives the aggressive basal-like subtype of pancreatic cancer.** Rushika Perera, UCSF, San Francisco, CA, USA.
B037. High throughput screening reveals a decrease in cell viability of pancreatic cancer cells after pharmacological inhibition of PIM kinases and mTOR. Brittany Nixon, North Carolin Central University, Durham, NC, USA.

B038. Impact of orexin-A and almorexant, two pancreatic cancer antitumoral molecules, on the regulation of OX1R expression at the cell surface. Stephanie Dayot, INSERM, U1149/CRI, Faculté de Médecine X. Bichat, Université Paris Diderot, PARIS, FRANCE.


B040. KCR are a new mouse model for PDA mechanism and therapeutics. Thomas Wilkie, UT Southwestern, Dallas, TX, USA.

B041. Loss of E2A in KC (KrasG12D; Pdx1-Cre) Mice Increases MYC Expression and Accelerates Growth of PanIn Lesions. Pamela Itkin-Ansari, SBPMDI, La Jolla, CA, USA.

B042. Loss of KDM6A upregulates EMT and activin signaling and promotes cell migration/invasion in pancreatic ductal adenocarcinoma. Zhujun Yi, University of Michigan, Ann Arbor, MI, USA.

B043. PR03. Lysyl oxidases suppress pancreatic cancer progression by inhibiting focal adhesion kinase signaling. Mario Shields, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

B044. Metabolic regulation of pancreatic identity and tumorigenesis. Barbara Nelson, University of Michigan, Ann Arbor, MI, USA.

B045. miR-34a accelerates KrasG12D driven pancreatic cancer. Ana Hidalgo Sastre, Klinikum Rechts der Isar, Munich, Bayern, Germany.

B046. Nitric oxide(NO•)/kynurenine/AHR signaling enhances disease aggressiveness in pancreatic cancer. Limin Wang, LHC/CCR, NCI, Bethesda, MD, USA.

B047. p120 catenin loss drives pancreatic cancer EMT and metastasis through activation of PTHrP-mediated calcium signaling. Jason Pitarresi, University of Pennsylvania, Philadelphia, PA, USA.

B048. PARTICIPATION OF IMPACT PROTEIN IN THE PROCESS OF TRANSLATION IN PANCREATIC ADENOCARCINOMA. Bárbara de Bellis, A.C. Camargo Cancer Center, São Paulo, Brazil.

B049. PR04. PDAC development and progression is dependent upon SHP2. Michael VanSaun, University of Miami, Miami, FL, USA.
**Poster Session B**
Sunday, Sept. 23, 2018
5:45-8 p.m.

**B050.** Piperlongumine induces JNK-mediated cell death in pancreatic cancer cells. Jiyan Mohammad, North Dakota State University, Fargo, ND, US.

**B051.** Positive feedback loops of enhanced canonical Wnt confers stemness traits to pancreatic cancer cells. Matthias Ilmer, Department of General, Visceral, and Transplantation Surgery, Hospital of the LMU Munich, Munich, Germany.

**B052.** Post translational O GlcNAcylation of SOX2 controls its tumor initiation properties in Pancreatic Cancer. Nikita Sharma, University of Miami, Miami, FL, USA.

**B054.** Targeting epichaperome networks in pancreatic cancer. Suhasini Joshi, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

**B055.** Targeting the metastasis suppressor NDRG1 to re-tune oncogenic cell signaling pathways in pancreatic cancer. Zaklina Kovacevic, University of Sydney, Sydney, NSW, Australia.

**B056.** The acinar transcription factor Ptf1a induces redifferentiation and growth inhibition of mouse and human PDAC cells. Shuba Narayanan, University of Utah, Salt Lake City, UT, USA.

**B057.** The role of PP2A B56α in pancreatic cancer cell plasticity. Brittany Allen-Petersen, Oregon Health & Science University, Portland, OR, USA.

**B058.** The role of the Frizzled2 receptor in PDAC progression. Payton Stevens, Van Andel Institute, Grand Rapids, MI, USA.

**B059.** Transcriptomic analysis and investigation of pathway alterations associated with pancreatic cancer in PDX models. Fiona O’Neill, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.

**B060.** Transcriptomic landscape of human epithelial and stromal cells isolated from cancer and normal tissue dissects cross-talks and deregulated signaling happening at cell-type level. Elisa Espinet, DKFZ - German Cancer Research Center and HI-STEM - Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.

**B061.** Translational control of DNA replication by 4E-BP1 in pancreatic cancer. Yvan Martineau, Inserm - CRCT, Toulouse, France.

**B062.** Ascites-derived-PDX models effectively recapitulate the gemcitabine-resistance observed in pancreatic cancer patients. Akihito Machinaga, KAN Research Institute, Inc., Kobe, Hyogo, Japan.

**B063.** Association of desmoplastic subtypes and immune composition in pancreatic ductal adenocarcinoma. Barbara Grünwald, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Poster Session B  
Sunday, Sept. 23, 2018  
5:45-8 p.m.

B064. Bicompartmental effects of the histone deacetylase inhibitor entinostat provide therapeutic benefits in pancreatic cancer. Gaoyang Liang, Salk Institute for Biological Studies, La Jolla, CA, USA.

B065. Blocking CXCLs–CXCR2 axis contributes to the survival in a mouse model of pancreatic ductal adenocarcinoma via reduced invasion and a shift of immune-inflammatory microenvironment. Makoto Sano, The University of Tokyo, Tokyo, Japan.


B067. Cancer stem cell-produced Lysophosphatidic Acid reprograms surrounding tumor cells to a stem-like state. Taha Rakshandehroo, University of California, San Diego, San Diego, CA, USA.

B068. Cholesterol metabolic restriction regulates pancreatic carcinogenesis and epithelial-to-mesenchymal transition. Igor Astsaturov, Fox Chase Cancer Center, Philadelphia, PA, USA.

B069. Circumventing the difficulties of targeting Tgfβ signaling in pancreatic cancer. Huocong Huang, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.

B070. Complement factor B is identified as a secreted protein involving in pancreatic cancer progression by comprehensive secretome analysis. Shigetsugu Takano, Department of General Surgery, Chiba University, Chiba, Japan.

B071. Defining the role of the hexosamine biosynthesis pathway in pancreatic cancer. Peter Kim, University of Michigan, Ann Arbor, MI, USA.

B072. Dissecting inflammatory microenvironment factors driving expression of Keratin 17, a hallmark of basal pancreatic cancer. Danielle Fassler, Stony Brook Medicine, Stony Brook, NY, USA.

B073. Dissecting the progenitor and chemosensory role of tuft cells in pancreatic cancer. Megan Hoffman, University of Michigan, Ann Arbor, MI, USA.

B074. Enkephalin rescue from ethanol and TNFalpha exposure: Decreased TRPV4 ion channel activity and increased cellular protection from injury in human pancreatic carcinoma cells. Terry McNearney, Biomedical Consultant-self employed, Galveston, TX, USA.

B075. Examining the effect of the RNA binding protein Musashi on macrophage polarization in pancreatic cancer. Francisco Mercado, UCSD Moores Cancer Center, San Diego, CA, USA.

B076. Expansion of stromal <i>Gli</i> expression during pancreatic ductal adenocarcinoma initiation. Michael Scales, University of Michigan, Ann Arbor, MI, USA.
Poster Session B  
Sunday, Sept. 23, 2018  
5:45-8 p.m.

**B077.** Experimental platform for studying the quiescent compartment of pancreatic cancer. Yogev Sela, University of Pennsylvania, Philadelphia, PA, USA.

**B078.** Exploiting the stromal paracrine LIF to light up pancreatic cancer therapy and diagnosis. Yu Shi, Salk Institute for Biological Studies, La Jolla, CA, USA.

**B079.** Extracellular matrix stiffness alters the pancreatic stellate cell secretome and transcriptome. Sonya Liu, University of Southern California, Los Angeles, CA, USA.

**B080.** Fibroblast heterogeneity during pancreatic carcinogenesis. Paloma Garcia, University of Michigan, Ann Arbor, MI, US.

**B081.** Functional characterization of pancreatic cancer. Valérie Irizarry-Negrón, University of Michigan, Ann Arbor, MI, USA.

**B082.** Functional optical probes for dynamic mapping of the chemical and biophysical tumor microenvironment in pancreas cancer. Christopher DuFort, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

**B083.** Hormone therapy for gender-specific PDA arising from mucinous cystic neoplasms. Martin Whittle, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

**B084.** PR02. Identification of functional heterogeneity of fibroblasts and their impact on riot immunity in pancreatic cancer. Josephine Darpolor, MD Anderson Cancer Center, Houston, TX, US.

**B085.** IL-1-induced JAK/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Giulia Biffi, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

**B086.** Improved fitness of pancreatic cancer cells adapted to nutrient deprivation. Pei-Yun Tsai, Boston Children’s Hospital, Boston, MA, USA.

**B087.** Inhibition of Autotaxin inhibits the desmoplastic response and reduces growth of pancreatic adenocarcinoma. Mozhdeh Sojoodi, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

**B088.** Inhibition of stromal remodeling and pancreatic cancer cell invasion by a cytoplasmic MT1-MMP binding protein. Gina Razidlo, Mayo Clinic, Rochester, MN, USA.

**B089.** Investigating the mechanisms driving macrophage polarization in pancreatic cancer. Rosa Menjivar, University of Michigan, Ann Arbor, MI, USA.
**Poster Session B**  
**Sunday, Sept. 23, 2018**  
**5:45-8 p.m.**

**B090. Investigating the role of fibroblast growth factor signaling in pancreatic stellate cells.** Adriana Spalwisz, German Cancer Research Center (DKFZ), Heidelberg, Germany.

**B091. Investigating the role of myeloid cells in the immunosuppressive microenvironment in pancreatic cancer.** Samantha Kemp, University of Michigan, Ann Arbor, MI, USA.

**B092. Islet amyloid polypeptide does not act as a tumour suppressor in pancreatic cancer.** Austin Taylor, University of British Columbia, Vancouver, BC, Canada.

**B093. Macrophage-Epithelial Metabolic Crosstalk Impairs Chemotherapy in Pancreatic Cancer.** Christopher Halbrook, University of Michigan, Ann Arbor, MI, USA.

**B094. Measuring the desmoplastic reaction using second harmonic generation microscopy in pancreatic cancer.** Prashant Bavi, Department of Laboratory Medicine and Pathobiology, University of Toronto; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

**B095. Modulation of tumor microenvironment by nab-paclitaxel plus gemcitabine plus cisplatin chemotherapy in the KPC transgenic mouse model.** Pawan Noel, Translational Genomics Research Institute, Phoenix, AZ, USA.

**B096. Myeloid cell derived HB-EGF plays contrasting roles in pancreatitis and pancreatic tumorigenesis.** Hui-Ju Wen, University, Ann Arbor, MI, USA.

**B097. NetG1/NGL-1 contribution to stromal regulation of innate immunosuppression and pancreatic cancer metabolic support.** Ralph Francescone, Fox Chase cancer Center, Philadelphia, PA, USA.

**B098. NF-kB regulates GDF15 to suppress macrophage mediated tumor surveillance in pancreatic cancer.** David Wang, Medical University of South Carolina, Charleston, SC, USA.

**B099. Novel immunosuppressive myeloid cell populations detected in PDAC with high dimensional mass cytometry and multiplex immunohistochemistry.** Meredith Stone, University of Pennsylvania, Philadelphia, PA, USA.

**B100. Nucleolin targeting decreases pancreatic cancer immunosuppression.** Ilaria Cascone, University of Paris Est (UPEC), ERL-CNRS 9215, Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), UPEC, Créteil, France.

**B101. Oncogenic Kras modulates the immune infiltration and function during Pancreatic Carcinogenesis.** Ashley Velez-Delgado, University of Michigan, Ann Arbor, MI, US.
B102. **Oncogenic Kras Regulates Glucose Dependent iRGD Tumor-Targeting in Pancreatic Cancer.**
Gregory Botta, Sanford Burnham Prebys Medical Discovery Institute, Scripps MD Anderson Cancer Center, La Jolla, CA, USA.

B103. **Pancreatic cancer-associated fibroblasts plasticity regulated by Prrx1 alters tumor differentiation by paracrine HGF signaling.** Karin Feldmann, Klinik und Poliklinik für Innere Medizin II; Klinikum rechts der Isar/Technische Universität München, Munich, Bavaria, Germany.


B105. **Pegvohyaluronidase alfa remodels the tumor microenvironment and increases chemotherapeutic efficacy in a preclinical model of PDA.** Curtis Thompson, Halozyme Therapeutics, 11388 Sorrento Valley Road, San Diego, CA, USA.

B106. **Prognostic value of CD8-positive T-cell density computed by quantitative image analysis using whole tissue sections of pancreatic ductal adenocarcinoma.** Yohei Masugi, Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

B107. **ROBO2 is a stroma suppressor gene in the pancreas through regulation of TGF-BETA.** Ilse Rooman, Vrije Universiteit Brussel, Brussels, Belgium.

B108. **Single cell resolution reveals MHC class II-expressing cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.** Ela Elyada, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

B109. **Smpd3 promotes tumorigenesis and regulates chemoresistance of pancreatic tumors.** Audrey Hendley, University of California San Francisco, San Francisco, CA, USA.

B110. **Stage-specific transcriptome analysis in human iPS model of Pancreatic Adenocarcinoma progression.** Jungsun Kim, Cancer Early Detection Advanced Research Center and Cancer Biology Research Program in Knight Cancer Institute, Department of Molecular and Medical Genetics, Oregon Health & Science University School of Medicine, Portland, OR, USA.

B111. **Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.** Matteo Ligorio, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

B112. **Targeting hyaluronan synthesis and signaling with BET inhibitors in PDAC.** Krishan Kumar, Northwestern University, Chicago, IL, USA.
B113. Targeting macrophage populations during development and progression of pancreatic cancer. Peter Storz, Mayo Clinic, Jacksonville, FL, USA.

B114. The biogenesis of exosome miR-1246 in human pancreatic cancer cells. Yi-Fan Xu, Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

B115. The prolyl isomerase PIN1 plays a critical role in the pancreatic tumor microenvironment. Ellen Langer, Oregon Health & Science University, Portland, OR, USA.

B116. The selective bromodomain inhibitor, INCB057643, a potential modulator of the tumor microenvironment, increases survival in the KrasG12D/+;Trp53R172H/+;Pdx-1-Cre (KPC) mouse model of pancreatic cancer. Ana S. Leal, Michigan State University, Department of Pharmacology and Toxicology, East Lansing, MI, US.

B117. Trapping of shed MSLN within pancreatic tumors causes low serum MSLN concentration. Christine Alewine, NCI- Center for Cancer Research, Bethesda, MD, USA.

B118. Tuft cells play a suppressive role in pancreatic injury and tumorigenesis. Kathleen DelGiorno, The Salk Institute, La Jolla, CA, USA.

B119. Tumor neoantigenicity accelerates early pancreatic adenocarcinoma progression. Samarth Hegde, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

B120. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. Corinne Bousquet, Cancer Research Center of Toulouse, Toulouse, France.


B122. Glutamine depletion drives AMPK-dependent macropinocytosis in cancer-associated fibroblasts. Yijuan Zhang, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.